Bevacizumab improves survival when added to chemotherapy in metastatic colorectal
cancer (mCRC). We assessed the safety and efficacy of bevacizumab in mCRC patients≥ …

The aim of the present study was to describe treatment outcomes for bevacizumab in
combination with chemotherapy based on data from the Czech registry of targeted therapies …

Background As of 2006, bevacizumab was available for the treatment of metastatic
colorectal cancer (mCRC) in British Columbia (BC). This study compares survival between …

Abstract Background. The Bevacizumab Regimens' Investigation of Treatment Effects
(BRiTE) study is a prospective, observational cohort study designed to elucidate safety and …

Background. After approval of bevacizumab in Germany in 2005 for the treatment of
unresectable advanced or refractory colorectal cancer (CRC), this observational cohort …

Background and objective The incidence rates of colorectal cancer (CRC) are increasing in
a number of different regions, and recent studies have indicated that addition of …

Purpose. This analysis pooled individual patient data from randomized controlled trials
(RCTs) to more thoroughly examine clinical outcomes when adding bevacizumab to …

Purpose Bevacizumab has demonstrated survival benefit in metastatic colorectal cancer
(mCRC) patients when combined with chemotherapy. Several randomized clinical studies …

Background There has so far been little information on the clinical effect of bevacizumab
against colorectal cancer in Japan. Hence, this study was conducted to retrospectively …

Background and Objectives: Colorectal cancer (CRC) is a leading cause of cancer-related
mortality and morbidity worldwide. Bevacizumab was approved for the treatment of …